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Despite improvements in the screening and local-regional therapy of
breast cancer, 30% of women who are diagnosed with invasive breast cancer
will develop metastatic disease during their lifetime. Adjuvant chemotherapy
is our best answer to this problem, but this requires the administration of
a toxic and expensive course of therapy to many patients to realize the benefit
in only a few. For every 10 patients who are node-negative and receive
adjuvant chemotherapy, only one breast cancer death will be prevented [1].
New approaches to therapy are needed that can eradicate micrometastatic
disease without significant morbidity. The interest in harnessing the power of
the immune system for this purpose is not surprising.
Although all researchers like to believe that their approaches are novel
and cutting-edge, immunotherapy in its most basic form dates back several
millennia to the intratumoral injection of infected purulent materials, as
documented in Eastern and Western ancient medical writings [2]. The
‘‘modern’’ age of immunotherapy, however, can be said to start with William
Coley, a surgeon at Memorial Hospital in New York. In 1893, he reported
that injecting an inoperable sarcoma with streptococcal broth cultures
resulted in tumor regression; when he stopped the injections, tumor growth
resumed. He followed this with an injection of a new culture that elicited
a life-threatening attack of erysipelas. The patient survived this episode, his
tumor regressed significantly, and he lived for 8 years. On the basis of these
results, Coley began treating patients who had inoperable disease, including
patients who had breast cancer, with ‘‘Coley’s toxin,’’ which was prepared
from Streptococcus pyogenes and Serratia marcescens [3].
The successes that were seen with Coley’s toxins were not as significant as
advances in surgery, radiation, and chemotherapy. Consequently, interest in
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processes through which the immune system eradicated infectious diseases
or tumors. Over the past few decades, our knowledge of the components and
mechanisms of the immune system has grown exponentially. Paralleling that
growth has been our interest in immunotherapy for cancer, including breast
cancer.
How does the immune system fight cancer?
The reason why immunotherapy is so attractive is the specificity; an
immune response can be directed against tumor-specific antigens (TAA)
through two mechanisms—the humoral response and the cellular response.
The humoral response is triggered by the interaction between the variable
region of an antibody with specific epitopes on cell-surface molecules. The
cellular response involves recognition of antigens by T-cell receptors (TCRs)
when they are presented by the cell in conjunction with the major histo-
compatibility complex (MHC) molecules. Antibodies are not capable of
detecting the small processed peptides onMHCmolecules on the cell surface,
so the nature of the antigens that are recognized by the humoral and cellular
arm is different. Whether a humoral or a cell-mediated immune response is
more important in generating antitumor immunity still is debated; however,
patients who exhibit both responses seem to fare better than those who
demonstrate only one type of response [4,5].
The initiation of an antitumor immune response rests with antigen-
presenting cells (APCs) to process and present tumor-related antigens. Pro-
teins are phagocytosed by APCs, partially digested into smaller polypeptides,
and bound to MHC class II molecules. After the antigen-MHC complexes
are transported to the cell surface they can be recognized by naı̈ve T
lymphocytes through the TCR. When a naı̈ve helper (CD4þ) T cell
recognizes the antigen, as well as costimulatory molecules that are present
on the APC, it becomes activated. Activation results in proliferation and
differentiation and the activated helper T cell can then help to promote
a cellular response (Th1) or a humoral response (Th2).
A Th2 response ultimately leads to the stimulation of B cells to proliferate
and differentiate into plasma cells through the secretion of B-cell stimulatory
cytokines (interleukin [IL]-4, IL-5, IL-10). Antibodies that are produced by
the plasma cells can recognize breast cancer cell surface antigens and kill
tumor cells by a variety of methods. One important method is antibody-
dependent cell-mediated cytotoxicity (ADCC), which involves the attach-
ment of tumor-specific antibodies to tumor cells and the subsequent
destruction of the tumor cell by immunocompetent cells, most commonly
the natural killer (NK) cell. Another way in which antibodies lead to tumor
death is through complement-dependent cell-mediated cytotoxicity, where
the recognition and attachment of complement-fixing antibodies to tumor-
specific surface antigens is followed by complement activation and cell death.
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recognizes antigen that is being presented on the surface of an APC. The
TCRs on cytolytic T cells recognize antigen that is presented on MHC class
I molecules. In the presence of costimulatory molecules on the APC and
cytokines that are released from the Th1 helper T cell (IL-12, interferon
[IFN]-c, tumor necrosis factor [TNF]-a), the cytolytic T cell is activated.
Once activated, cytolytic T cells destroy tumor cells by way of TCR
recognition of tumor-specific antigen that is presented on MHC class I
molecules at the tumor cell surface. They bind to the MHC class I receptor–
tumor antigen complex and destroy the tumor cell by way of the release of
granules that contain granzyme B and perforin and by way of induction of
Fas/Fas ligand apoptosis.
Breast cancer–specific antigens
The success of immunotherapy rests upon the presence of breast cancer-
specific antigens to which either a humoral or cellular response can be
initiated. While breast cancers have been classically categorized as
nonimmunogenic, several tumor proteins have been identified to which an
immune response can be generated (Table 1) [6]. Mutational antigens are
one category of TAA that is encoded by the multiple genetic mutations that
are present in malignant cells. The aberrant proteins that result from genetic
alterations can deprive the cell of the wildtype functions (and result in
malignant transformation) and lead to new proteins that are immunogenic.
Differentiation antigens are antigens that are shared by cancer cells and
normal cells; typically, they are overexpressed in cancerous tissue. In breast
cancer, the most important of these antigens is the human epidermal growth
Table 1
Potential targets for immunotherapy in breast cancer
Antigen [reference] Expression (%) Type Response
p53 [7,8] 17 Mutational Cellular
CEA [9] 50 Differentiation Humoral and cellular
NY-BR-1 [10] 80 Differentiation Humoral
HER-2/neu 30 Amplified/overexpressed Humoral and cellular
MUC-1 80 Differentiation/mutational Humoral
NY-BR-62 [10] 60 Amplified/overexpressed Humoral
NY-BR-85 [10] 90 Amplified/overexpressed Humoral
D52 [10] 60 Amplified/overexpressed Humoral
Mammoglobin [11] 23 Amplified/overexpressed Humoral and cellular
NY-ESO-1 [12] 24 Cancer-testis antigen Humoral and cellular
MAGE-3 [12] 14 Cancer-testis antigen Humoral and cellular
SCP-1 [12] 30 Cancer-testis antigen Humoral
SSX-1 [13] 12 Cancer-testis antigen Humoral
SSX-4 [13] 14 Cancer-testis antigen Humoral
CT-7 [12] 30 Cancer-testis antigen Humoral
Abbreviations: CEA, carcinoembrionic antigen; CT-7, cancer testis-7; NY-BR, New York
Breast; NY-ESO, New York Esophagus; SSX, synovial sarcoma-x.
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protein is expressed at low levels on normal tissue but is overexpressed in
many types of malignancies, including 30% of breast cancers [14]. This
overexpression makes HER-2/neu an appealing molecular target for drug
therapy, particularly because its heightened expression is associated with
poorer clinical outcome [15].
Another breast cancer antigen that is of interest is mucin (MUC-1),
a membrane-bound glycoprotein that consists of a polypeptide core and
numerous carbohydrate side chains. The version of MUC-1 that is expressed
on breast cancers differs from that in normal tissues in that the carbohydrate
side chains are shorter and the peptide backbone is more exposed. As a cell
surface glycoprotein, it is most efficient in inducing a humoral response; the
presence of a MUC-1 specific IgG and IgM antibody response may be
associated with a longer disease-free survival [16]. There also seems to be
evidence for a natural immunization against MUC-1 during pregnancy,
which has been proposed as one explanation for why breast cancer is less
common in multiparous women [17].
Other differentiation antigens are present in the same form on normal
epithelial cells and cancer cells. It is possible that an immune response to
these antigens could stimulate an autoimmune destruction of the normal
tissues that express them. In the treatment of melanoma, for example, this
would result in vitiligo, which has been described as a side effect of
melanoma immunotherapy and is associated with an improved prognosis
[18,19]. Although mastitis may not be an acceptable side effect of therapy,
targeting these antigens would be of less concern in the adjuvant setting
after a bilateral mastectomy.
Cancer-testis antigens are antigens that present on germ line cells but not
on somatic cells. Changes in transcriptional regulation in cancer cells can
lead to expression of these antigens. Because germ line cells do not express
MHC molecules, these antigens normally are silent; however, when
expressed on cancer cells, they are capable of eliciting an immune response.
Examples of cancer-testis antigens in breast cancer include MAGE-3 and
SSX-expressed proteins.
Techniques, such as CD8þ and CD4þ T-cell epitope cloning, serum
antibody expression cloning (SEREX), and genomic approaches, are making
it easier to identify breast cancer antigens. It is reasonable to expect that over
the next few years there will be a dramatic increase in the number of identified
breast cancer antigens. Which antigens will be the best targets and which
methods to elicit a clinically relevant response to those antigens will be the
most effective, will remain the core questions in immunotherapy research.
Role of the immune system in breast cancer
When discussing tumor immunology, one cannot help but to think
immediately of melanoma, which has emerged as the primary cancer model
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including the ease of studying melanoma in the laboratory (allowing for
the identification of multiple melanoma-specific antigens) and the lack of
effective adjuvant therapies (resulting in a higher portion of patients who is
available for clinical testing). Another reason is the clinical evidence that
there is a natural role of the immune system in the development and pro-
gression of this melanoma. Melanoma often presents as metastases without
evidence of a primary tumor that presumably has undergone immune-
mediated regression. Histopathologic evidence of tumor regression is
observed frequently within primary melanoma specimens, along with lym-
phocytic infiltration. It also is not uncommon for melanoma to remain
dormant for some time (up to 20 years after diagnosis); this suggests
a balance between the tumor and the host immune system.
This begs the question, ‘‘Is there a baseline role of the immune system in
the natural history of breast cancer?’’. Unidentified primary tumors and long
intervals between diagnosis and recurrence certainly occur with breast
cancer; however, neither is as common as it is with melanoma. If the immune
system does suppress the development of a cancer, one would expect that the
incidence would increase in patients who do not have a competent immune
system. This increase is seen in melanoma; the incidence of melanoma
increases dramatically in immunocompromised transplant recipients and
these patients often present with multiple lesions [20,21]. This same
observation, however, has not been seen with breast cancer [22].
In melanoma, another argument for a prominent role of the immune
system is the presence of lymphocytic infiltrate and evidence of tumor
regression. Tumor-infiltrating lymphocytes (TILs) also have been identified
in breast cancer. One might expect that if the host’s immune system can
recognize and impede the growth of breast cancer, then those tumors with
a more intense lymphocytic infiltration would be associated with a better
prognosis. In one study of more than 1900 breast tumors, evidence of
lymphocytic infiltration [23] was an independent predictor of prognosis on
multivariate analysis (including tumor size and nodal status) in women who
were younger than 40 years of age, but not in women who were older than
40; however, other studies found that lymphocytic infiltration is a poor
prognostic sign [24].
Evidence of a natural immune recognition of breast cancer also can be
identified systemically. Some patients who have breast cancer have
detectable immunity to HER2, antibody responses, and, to a lesser degree,
T-cell responses [25–28]. Cytotoxic T lymphocytes that are specific for
tumor-associated mucin can be detected in patients who have cancer that
have adenocarcinomas that overexpress mucin [29]. Is this immune response
clinically relevant? If there is a natural role to the immune system to the
progression of breast cancer, the presence of a response should correlate
with outcome. In some cases this has been suggested; for example, the
presence of a MUC-1–specific antibody response may be associated with
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evidence for this is scant and conflicting. In the case of HER2, it is difficult
to separate any potential impact of a natural HER-2/neu immunity because
of multiple interrelated variables. HER-2/neu monoclonal antibody (mAb)
and T-cell responses occur when the cancer overexpresses increased levels of
HER2/neu, which, in itself, is associated with aggressive disease, response to
chemotherapy, and poor outcome. There also are cases where evidence of an
immune response seems detrimental. As an illustration, it is well-documented
that a percentage of patients exhibit a delayed-type hypersensitivity (DTH)
response to a skin test with autologous tumor extracts, including breast
cancer [30]. Of 56 patients who had breast cancer who were tested for a DTH
response to their tumors and were followed for at least 2.5 years, survival was
worse in patients who had a positive response [30]. The evidence remains
extremely unclear as to whether the immune system plays any significant role
in the development and progression of breast cancer.
Methods of generating an immune response
It would seem, therefore, that researchers who are interested in breast
cancer immunotherapy are starting at a disadvantage compared with their
colleagues in melanoma. The lack of evidence for a natural role of the
immune system in the evolution of breast cancer does not imply necessarily
that it is not possible to deliver or generate such a response. One method is
passive immunotherapy—the delivery of antibodies or cells that have been
sensitized previously to host tumor antigens. With passive immunotherapy,
the host need not mount an immune response; the therapeutic agent directly
or indirectly mediates tumor killing. One of the best known examples of
passive immunotherapy is trastuzumab (Herceptin), a monoclonal antibody
to HER-2/neu, and an approved treatment for stage IV breast cancer. The
other method for stimulating an immune response is active immunotherapy
in which the intervention prompts the host to mount an immune response.
Active nonspecific immunotherapy uses agents that stimulate the immune
system globally, but do not recruit specific effector cells. Active specific
immunotherapy is designed to elicit an immune response to one or more
tumor antigens; the prime example is the use of vaccines.
Active nonspecific immunotherapy
Immunostimulants
Coley’s toxin represented the earliest form of active immunotherapy that
used a nonspecific immunostimulant. A more familiar approach is the use of
bacille Calmette-Guérin (BCG), an attenuated form of the tubercle bacillus.
Although first used as a vaccine against tuberculosis, it ultimately was
discovered to be a potent immunostimulant that was capable of preventing
tumor growth in mice [31]. BCG has been studied in several tumor types and
remains an intralesional therapy of early stage bladder cancer. BCG was
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Although rates of remission were similar between chemotherapy and BCG
compared with chemotherapy alone, remissions seemed to last longer with
the addition of BCG [32,33]. In a randomized trial of patients who had stage
II breast cancer and were given adjuvant therapy with chemotherapy and
tamoxifen with or without BCG, BCG failed to improve overall disease-free
survival. The killed vaccine, Corynebacterium parvum, is another immunos-
timulant that has been studied extensively. Again, based on some promising
early data [34], C parvum was studied in combination with adjuvant
chemotherapy for patients who had stage II breast cancer; it failed to
improve disease-free survival [35]. Neither BCG nor C parvum has a role in
breast cancer treatment, although they may serve as adjuvants to tumor-
specific vaccines.
Other immunostimulants are not bacterial in nature, but rather are
synthetic. Levamisole was developed originally as a veterinary antihel-
minthic, but was shown to have immunopotentiating properties. Although
levamisole is beneficial in colon cancer, its use in breast cancer yielded mixed
results with significant toxicities [36–39]. Polyadenylate:polyuridylate (poly
A:U) is another synthetic immunostimulant. This is a polynucleotide
polyriboinosinic acid that seems to work primarily through induction of
interferon. A randomized trial of poly A:U as adjuvant therapy after
mastectomy and radiation resulted in a 4-year relapse-free survival rate of
77% compared with 57% in controls [40].
Cytokines
Cytokines are naturally-occurring soluble proteins that are produced by
mononuclear cells of the immune system. They can affect the growth and
function of cells through interaction with specific cell-surface receptors.
With advancements in molecular biologic techniques, it became possible to
clone the genes for these cytokines and mass produce pure forms in large
amounts. This allowed researchers to study their function and to explore
their use as therapeutics. More than 50 cytokines have been isolated to date
and several have been approved by the U.S. Food and Drug Administration
(FDA) for the treatment of a variety of malignancies; however, they have
had minimal impact on the treatment of breast cancer.
The interferons were described originally as proteins that are produced
by virally-infected cells that protect against further viral infection through
a variety of effects. These include the increased antigen presentation by way
of increased expression of MHC and antigens, enhancement of NK cell
function, and the enhancement of ADCC. In addition, the interferons exert
direct antiangiogenic, cytotoxic, and cytostatic effects. There are several
subtypes of interferons, including IFN-a, IFN-b, and IFN-c.
IFN-b and IFN-c have been studied in breast cancer but their potential for
cancer therapy remains unclear [41]. Although IFN-c clearly has immunos-
timulatory effects, it also has inhibitory effects on antigen presentation,
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HER2/neu [42,43]. Several hematologic and solid tumors have proved
responsive to IFN-a, including chronic myelogenous leukemia, cutaneous T-
cell lymphoma, hairy cell leukemia, malignant melanoma, and Kaposi’s
sarcoma. Few clinical trials have examined IFN-a against breast cancer and
demonstrated only minimal responses with considerable toxicity [44,45].
Originally, IL-2 was described as the ‘‘T-cell growth factor,’’ because it is
required for the differentiation and proliferation of activated T cells. As
such, it seems like an ideal choice for immunotherapy. The major drawback
of IL-2 is the significant dose-related toxicity. IL-2 leads to significant
interstitial edema and lymphoid infiltration into vital organs that can lead to
severe hypotension and resultant ischemic damage to the heart, liver,
kidneys, and bowel. This limits the use of IL-2 to patients who have excellent
performance status, normal pulmonary and cardiac function, and no active
infections. IL-2 alone is an effective therapy in patients who have metastatic
melanoma and metastatic renal cell carcinoma, but there is minimal evidence
to support its use in breast cancer. The possible role of other cytokines with
anticancer properties, such as IL-12 or granulocyte macrophage-colony
stimulating factor (GM-CSF), is being investigated.
Passive immunotherapy
The potential for therapy with immunostimulants or cytokines rests on
the assumption that the immune system has at least a minimal capacity to
recognize and ablate tumor cells. Through a global augmentation of the
immune system, that baseline anti-tumor response will also be augmented,
hopefully to clinically relevant levels. Passive immunotherapy assumes that
there is no significant inherent immune response and works through the
administration of preformed elements of the immune system. This may be of
great benefit in breast cancer, in which a baseline immune response does not
seem to be as effective in inhibiting the growth of the cancer.
Monoclonal antibodies
The process by which the body generates an antibody response can be
circumvented by the intravenous administration of antigen-specific mono-
clonal antibodies. In breast cancer, the most well-known is trastuzumab
(Herceptin), which is FDA-approved for the treatment of HER-2/neu-
expressing tumors. The targeting of other breast cancer antigens, including
MUC-1 and epithelial cell adhesion molecule (EpCAM), with monoclonal
antibody therapy is under clinical and laboratory investigation. Much of the
appeal of this approach is that monoclonal antibodies are easy to mass
produce, standardize, and administer. This significantly increases their
clinical usefulness as compared with other methods of immunotherapy.
Trastuzumab (Herceptin) is a monoclonal antibody that is directed at
HER-2/neu. Because normal body tissues only express HER-2/neu at low
levels, trastuzumab is a tissue-selective treatment for breast cancer and was
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monotherapy for breast cancer [46]. When used in conjunction with
traditional chemotherapy, trastuzumab increased time to disease pro-
gression (7.4 versus 4.6 months, P\ .001), decreased rate of death at 1 year
(22% versus 33%, P = .008), and increased patient survival compared with
chemotherapy alone (median survival, 25.1 months versus 20.3 months
P = .046) [47].
Although trastuzumab is touted by many investigators as evidence for the
potential of immunotherapy in breast cancer, the mechanism by which
trastuzumab kills tumor cells has not been defined completely and might not
be purely immunogenic. At the molecular level, the binding of trastuzumab
to the HER-2/neu protein causes the complex to be internalized and broken
down; this decreases the phosphorylation of the neu tyrosine kinase and
eliminates its signaling capacity to promote tumor growth. This suggests that
trastuzumab acts primarily as an antagonist to the epidermal growth factor
receptor [48]. This is not to say that the immune systemmay not play a role in
trastuzumab’s mechanism of action. Treatment with trastuzumab increased
the killing of HER-2/neu overexpressed cancer cells by HER-2/neu–specific
cytotoxic lymphocyte (CTL)s in vitro [49] and enhanced ADCC [50], which
may be an important mechanism for trastuzumab-induced responses in vivo
[51]. It may be possible to increase the immunologic component by
combining Herceptin with systemic cytokines [52,53]. By whatever mecha-
nism trastuzumab kills tumor cells, it is an effective tool against HER-2/neu–
overexpressed breast cancers and improves the prognosis of the disease.
Although trastuzumab was effective against HER-2/neu positive breast
cancers, it is only expressed on 30% of those malignancies, which excludes
most patients from this therapy. MUC-1 is expressed in 80% of breast
malignancies, so passive immunotherapy against MUC-1 would be
applicable to a much larger fraction of women who has breast cancer.
The low level of glycosylation on the aberrant MUC-1 that is present on
breast cancer cells unmasks epitopes that are not exposed on normal mucin
and creates targets for tumor-specific antibodies [54]. Preclinical research
identified several anti–MUC-1 mAbs that are effective in killing breast
cancer cells. DF3 is one mAb that is directed at MUC-1; it increased
antigen-directed phagocytosis and cytolysis of MUC-1–expressing human
breast cancer cells in vitro [55]. Edrecolomab, another monoclonal
antibody, is directed against the EpCAM, which is expressed on several
types of cancers, including colon and breast. Braun et al [56] measured the
efficacy of edrecolomab as a monotherapy in the elimination of tumor cells
from bone marrow aspirates in patients who had advanced metastatic breast
cancer (n = 10). The number of EpCAM-expressing cells decreased in all 10
patients in the study and 4 patients had complete elimination of EpCAMþ
cancer cells. Another study investigated edrecolomab’s efficacy in eliminat-
ing bone marrow metastasis of breast cancer following chemotherapy [57].
After completion of chemotherapy, 9 of 14 patients remained positive for
10 M.S. Sabel, M.A. Nehs / Surg Oncol Clin N Am 14 (2005) 1–31the EpCAMþ antigen and were treated. This mAb treatment eradicated all
EpCAMþ cancer cells in 7 patients and greatly reduced the number in the
other 2 patients. Although treatment with anti–MUC-1 or anti-EpCAM
mAb are experimental, this line of therapy looks promising, particularly as
a complement to other therapies.
Adoptive immunotherapy
Although more complex than delivering monoclonal antibodies, the
cellular arm of the immune system also may be used as passive immu-
notherapy. A cellular immune response to cancer may be more effective than
an antibody response; however, attempts to stimulate a cellular response
through immunostimulants or vaccines has been difficult. Therefore, the
passive administration of cells with antitumor activity to the tumor-bearing
host has generated significant interest. This cellular infusion therapy, known
as adoptive immunotherapy, involves harvesting cytotoxic T lymphocytes,
NK cells, or mononuclear cells from the patient (autologous) or a donor
(allogeneic); selecting and expanding them in vitro; and delivering the
activated, tumor-specific cellular inoculum to the patient.
Early trials of the adoptive transfer of allogeneic lymphocytes demon-
strated little or no clinical effect [58,59]. Slightly more promise has been seen
with harvesting autologous lymphocytes, activating them in vitro, and
delivering them back to patients. These lymphocytes may be obtained from
the peripheral blood or bone marrow of patients who have breast cancer
[60,61]. The primary obstacle has been the generation of sufficient numbers
of tumor-specific cells for transfer. Minimal benefit is seen when lym-
phocytes are activated in a nonspecific manner [62,63] because there is
a scarcity of tumor-specific T cells in the periphery. Stimulating lymphocytes
in the presence of autologous tumor cells [64], genetically-modified tumor
cells [65], or tumor-pulsed dendritic cells [66] can increase the specificity of
the lymphocytes, and potentially, the clinical response.
A richer source of tumor-specific lymphocytes may be the TILs.
Cytotoxic T lymphocytes that are isolated from the breast tumors seem to
be tumor-specific and demonstrate cytolytic activity against autologous cell
lines [67]. Although TILs seem particularly attractive for adoptive therapy
of melanoma, their use in breast cancer shows less potential [68–70].
Adoptive immunotherapy of breast cancer with expanded TILs faces several
obstacles, particularly in obtaining adequate numbers. Primary breast
tumors often are small (\2 cm); after margin status is determined on the
lumpectomy specimen, there is minimal tissue available from which to
expand TILs. It also is difficult to establish a cell line in vitro from the
tumor, which is needed to test the lytic activity of the T cells before infusion.
In stage IV disease, metastatic deposits often are difficult to access (eg, bone,
lung, brain) which prevents T-cell harvesting.
An alternate source may be located in the tumor-draining lymph nodes
(TDLNs). Tumor-reactive T lymphocytes can be expanded from regional
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cells demonstrate a tumor-specific response [71]. Okino et al [72] obtained
lymphocytes from regional lymph nodes and peripheral blood from patients
who had breast cancer with liver metastases. They saw clinical responses
when these cells and OK-432, a biologic response modifier, were
administered by way of the intra-arterial route into the liver.
With sentinel node biopsy becoming routine in the management of breast
cancer, the lymph nodes that drain the tumor directly are sectioned thinly
and scrutinized carefully for the presence of micrometastases. This makes
it difficult to obtain significant quantities of T cells from the TDLNs. An
alternate approach is to vaccinate the patient at an alternate site and harvest
the vaccine-draining lymph nodes (VDLNs). Chang et al [73] demonstrated
the feasibility of this approach in patients who had advanced melanoma or
renal cell carcinoma. They vaccinated the patients with an autologous tumor
vaccine that was admixed with BCG and expanded T lymphocytes ex vivo in
the presence of IL-2. This approach stimulated complete and partial
responses in some patients [74]. Genetic modification of the vaccinating cells
to secrete GM-CSF may enhance the T-cell reactivity of the VDLN cells
further against breast cancer antigens [75,76]. Although this exact approach
would be hampered by the difficulties in creating autologous vaccines in
patients who have breast cancer, an alternate approach that uses allogenic
cellular or peptide vaccines may be feasible [77,78].
In addition to T cells, NK cells may have the potential for adoptive
immunotherapy of cancer because their natural role in the body is fighting
virally-infected cells and cancerous cells [79]. The genetically-modified NK
cell line, NK-92-scFv(FRP5)-f, expresses a chimeric antigen receptor that is
specific for HER2/neu [79]. In vitro, NK-92-scFv(FRP5)-f cells were
effective at inducing apoptosis in cells that overexpressed HER2/neu and
could eliminate them completely with prolonged incubation in culture [79].
NK cells plus IL-2 also were examined as an adoptive treatment for
metastatic breast cancer following an autologous blood stem cell infusion
[80]. Non-MHC restricted cell-based therapies also have been examined.
Lymphokine activated killer (LAK) cells are generated in vitro by
incubating the patient’s peripheral blood mononuclear cells (PBMC) with
high-dose IL-2 and are capable of killing cells in a non-MHC–restricted
fashion. Adoptive immunotherapy with LAK cells and high-dose IL-2 had
minimal effect in patients who had breast cancer [81]. The human leukemic
cell line, TALL-104, also killed cancer cells in a non-MHC–restricted
fashion and induced tumor regression in breast tumor–bearing mice [82]. In
a phase I clinical trial, 15 patients who had metastatic breast cancer received
the adoptive transfer of TALL-104 cells [83]. Specific CTL activity
developed in 7 patients and 5 patients had stable disease for 2 to 6 months.
Adoptive immunotherapy is at an early stage in its development and the
cost, complexity, and variability of these strategies limit their use to
investigational studies. In addition, the lack of available tumor in many
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approaches. Additional research and increased understanding of the
complex interactions that are involved will define better the potential of
adoptive cellular therapy in the treatment of breast cancer.
Active specific immunotherapy (vaccines)
The goal of active specific immunotherapy is to generate a host immune
response to known or unknown tumor-associated antigens. Generally, these
are referred to as cancer vaccines, although this term can be misleading. We
are used to referring to vaccines as protective against infectious agents (ie,
they are meant to stimulate the immune system against antigens that it has
not seen). In contrast, cancer vaccines are designed to stimulate an immune
response against antigens on cells to which the immune system already has
been exposed.
Many different vaccine strategies are under investigation, each with
advantages and disadvantages in regard to clinical feasibility and cost, the
number of antigens that is available, and the mechanism of response
(cellular, humoral, or both; Table 2) [84]. Some vaccine strategies use
specific peptide antigens. These are highly purified and, therefore, are less
likely to contain potentially irrelevant material. This has important
implications regarding standardization and quality control; however, single
antigens are less immunogenic and can be vulnerable to antigen modulation.
Several other approaches use whole cells that contain many antigens. These
Table 2
Breast cancer vaccine therapies






Single antigen, easy for
tumor to escape recognition.
Antiidiotype vaccines Standardization and
quality control.
Single antigen, easy for
tumor to escape recognition.
Increased immunogenicity
(breaks tolerance).
Allogeneic cellular vaccines Does not require
autologous tumor.




Autologous cellular vaccines Highly patient-specific. Requires harvesting tumor and
creating cell lines.
Do not need to know
tumor-specific antigens.
Costly and labor-intensive.
Dendritic cell vaccines Strongly immunogenic. Either need known antigens or
may require harvesting
tumor and creating cell lines.
Costly and labor-intensive.
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Generally, these vaccines are more difficult to standardize and analyze;
theoretically, this approach has the greatest potential for eliciting an
immune response that is directed against multiple antigenic targets.
Breast cancer antigen vaccines
For a known, breast cancer–specific antigen, it is possible to use that
protein as a vaccine—either the entire protein, which allows the patient’s
own immune system to cleave and bind peptides—or just selected
immunogenic peptides. Immunizing the patient with the protein probably
would not be sufficient because most of these antigens are weakly
immunogenic. To improve the immunogenicity, the peptides often are
delivered to the patient with an immune adjuvant that is meant to induce
inflammation and push the immune process toward immunity, rather than
tolerance. BCG or DETOX (‘‘detoxified Freund’s adjuvant,’’ composed of
monophosphoryl lipid A and a purified mycobacterial cell-wall skeleton) are
examples of adjuvants that are meant to cause a generalized or nonspecific
inflammatory response that will increase the likelihood of recognizing the
vaccinating antigens. Cytokines also have been given simultaneously with
the vaccines to stimulate the immune response further.
Even when combined with adjuvants or cytokines, peptide vaccines are
easy to standardize, mass produce, and administer. This makes it simple to
test the vaccine effectively and has important implications regarding quality
control, cost-effectiveness, and clinical usefulness, particularly in the
adjuvant setting. Conversely, these vaccines are limited by the fact that even
if a peptide vaccine is immunogenic, it may not be the ‘‘right’’ vaccine for
many patients. Commonly-expressed tumor antigens are not present on all
patients’ tumors or may be present in varying degrees (see Table 1). In
addition, the T cell’s recognition of an antigen depends on the presentation of
that antigen on a specific MHC molecule. Only certain HLA phenotypes can
present any given peptide to induce an immune response, so they only will
function on a limited subset of patients. A classic example is that of the
MART-1/Melan-A antigen in melanoma. The antigen is expressed by 80% of
melanomas, but the peptide only binds to HLA-A2. Because approximately
45% of whites have HLA-A2, only 36% (80% of 45%) of patients who have
melanoma and are given a MART-1/Melen-A vaccine would see a benefit.
There is tremendous interest in MUC-1 vaccines because MUC-1 is
expressed on 80% of breast cancers and higher circulating antibodies to
MUC-1 in women who have early breast cancer and is associated with an
improved disease-free and overall survival [16]. Early data on MUC-1
vaccines demonstrated promising results [85]. Sixteen patients who had
metastatic breast carcinoma were immunized with a MUC-1 peptide plus
keyhole limpet hemocyanin (KLH) and DETOX. This resulted in anti–
MUC-1 IgG antibodies in 3 of 16 patients and anti–MUC-1 CTL activity
in 7 of 11 patients [86]. A mannan–MUC-1 fusion protein was given to
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resulted in anti–MUC-1 IgG antibodies in 13 of 25 patients and MUC-1–
specific T-cell proliferation in 4 of 15 patients [87]. Ongoing research will
determine the clinical impact of MUC-1 vaccines.
Given the success of Herceptin, there has been considerable work in
creating Her-2/neu vaccines [88]. Immunization with a HER-2/neu vaccine
can result in DTH peptide-specific responses in skin and specific T-cell
responses in peripheral blood lymphocytes [89,90]. Phase I studies of HER-2/
neu vaccines showed low levels of antitumor activity despite a detectable
immune response [86,91–94]. HER-2/neu is a 185-kd protein with no clear
consensus as to which part is the optimal target for vaccination. Attempts to
identify the optimal oligopeptide within the HER-2/neu protein and the use
of different adjuvants led to new vaccine strategies, including prevention of
disease and treatment of patients who are of a specific HLA subtype [95–101].
Besides cell surface proteins, carbohydrate tumor–associated antigens
may be targets of vaccines [102,103]. Sialyl-TN (STn) is a carbohydrate that
associates with the MUC-1 mucin. The cancer vaccine, Theratope (Biomira
Inc., Alberta, Canada), consists of STn conjugated to KLH as a carrier
protein and DETOX as an adjuvant [104,105]. Seven of 12 patients who had
metastatic breast cancer and were vaccinated with Theratope had a partial
clinical response or stabilization of their disease [106]. A follow-up
prospective trial randomized patients to receive Theratope with or without
intravenous (IV) or oral low-dose cyclophosphamide. A survival advantage
was seen in patients who received the vaccine with IV chemotherapy. A
phase III trial randomized 1028 women who had metastatic breast cancer
that was stable or in remission to receive IV cyclophosphamide followed by
Theratope or cyclophosphamide that was followed by a vaccine of KLH
and DETOX. Early reports demonstrated no overall difference in time-to-
disease progression or survival; however, analysis of the subset of patients
that received hormonal therapy showed a trend toward increased time-to-
disease progression. It is possible that patients who were not on hormonal
therapy progressed and were taken off Theratope before their immune
systems had time to obtain a significant immune response. Further research
into the potential use of Theratope is ongoing.
Anti-idiotype vaccines
Cell surface gangliosides may be weakly immunogenic as a result of
exposure to the immune system and the development of tolerance. A novel
vaccination method to overcome this tolerance is the administration of anti-
idiotype antibodies. Anti-idiotype antibodies exploit the fact that the
immune system uses a network of interacting antibodies to mount a response
against a specific antigen [107,108]. According to this ‘‘network hypothesis,’’
an external antigen is recognized by specific idiotypes that are expressed by
antibodies and TCRs. Antibodies that are produced against an antigen
can generate a series of anti-idiotype antibodies that mimic the
15M.S. Sabel, M.A. Nehs / Surg Oncol Clin N Am 14 (2005) 1–31three-dimensional structure of the original antigen. This would be like
making a mold of the inside of a lock to reproduce the structure of the key
that fits it. Thus these anti-idiotype antibodies can induce specific immune
responses that are similar to the responses that are induced by the original
antigen [109,110]. For use as immunotherapy, antibodies are raised against
anti-ganglioside antibodies so that the variable region of the antibodies
essentially are mirror-images of the ganglioside itself, only composed of
protein. When an immune response occurs to this mirror-image protein, it
also is cross-reactive against the original nonprotein antigen [111,112].
Several advantages to anti-idiotype vaccines are related to the fact that they
do not depend on the availability of large amounts of pure antigen, which
often is a limiting economic factor in vaccine production. Also, any acquired
tolerance to the original antigen can be broken by using a different
molecular form of the same antigenic moiety (in this case, the protein
antibody instead of the nonprotein ganglioside); this improves upon the
immunogenicity of standard antigen vaccines. Anti-idiotype vaccines are
under investigation in breast cancer [113–115].
Autologous cellular vaccines
Peptide vaccines are applicable only if one has a target antigen in mind.
Presumably, any patient’s cancer may have multiple antigens to which an
immune response may be directed. Using the patient’s cancer as the vaccine
precludes the need to identify these antigens specifically. Theoretically, this
approach ensures that all biologically-relevant antigens are presented to the
immune system. Autologous tumor cells are harvested from the patient,
irradiated, and returned to the patient to stimulate a tumor-specific immune
response along with adjuvants to increase the immunogenicity. There are
several drawbacks to autologous cellular vaccines. First and foremost, the
approach is limited to individuals who have sufficient tumor to prepare
a vaccine. This has restricted trials to patients who had adequate tumor
from which cell lines could be created. This is extremely difficult in patients
who have breast cancer because they rarely have a large amount of
harvestable tumor, and in whom establishment of cell lines is difficult.
Dillman et al [116] attempted to establish cell lines from patients who had
breast cancer for autologous vaccines but were successful in only 8 of 115
samples (7%).
Despite the difficulties, several investigators have examined the use of
autologous cellular vaccines in breast cancer. Wood and Baynes [117]
administered autologous irradiated breast cancer cells intradermally with
GM-CSF to patients who had stage IV breast cancer. Immune responses
were seen in 11 of 12 patients but clinical outcome was not reported. Ahlert
et al [118] vaccinated 90 women who had primary or metastatic breast
cancer with a Newcastle disease virus–modified, irradiated tumor cell
vaccine. In the patients in whom a vaccine could be established with
maximum viability, there was a trend toward improved survival which
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complexities that are inherent in procuring tumor and preparing a vaccine,
have, to date, precluded widespread conduct of multi-institutional trials to
test formally the efficacy of these vaccines. Treatment would be extremely
costly and is feasible at a limited number of academic institutions.
Allogeneic tumor cell vaccines
Several breast cancer–associated antigens are shared among a large
number of patients. Therefore, it is reasonable to expect that one could
create a vaccine from cultured cell lines that would stimulate an anti-tumor
immune response in any patient who shared some of those antigens. This is
the principle behind allogeneic tumor cell vaccines. This approach offers
several advantages over autologous vaccines in breast cancer. Specifically,
allogeneic vaccines are readily available for patients who lack sufficient
tumor to produce an autologous tumor cell vaccine and can be standardized,
preserved, and distributed in a manner akin to any other therapeutic agent.
Allogeneic cellular vaccines are being investigated as adjuvant therapy in
melanoma. These include Canvaxin (Cancer Vax, Carlsbad, California), an
allogeneic melanoma vaccine that is composed of three viable irradiated
melanoma cell lines that are chosen specifically for their high content of
immunogenic melanoma- and tumor-associated antigens [119], andMelacine
(Corixa, Seattle, Washington), a lysate of two homogenized melanoma cell
lines that are combined with the adjuvant, DETOX [120].
To augment the immunogenicity of allogeneic cellular vaccines, cells can
be modified genetically ex vivo. One approach is to modify the cells
genetically to produce cytokines which results in a sustained release of those
cytokines at the site of the vaccine. Locally-secreted cytokines can recruit
antigen-presenting cells at the vaccine site and enhance in vivo lymphocyte
activation and expansion, thereby augmenting the immune response.
Another method for increasing the immunogenicity of cellular vaccines is
to transfect the cells with CD80 (B7-1), a costimulatory that is present on
antigen-presenting cells. Essentially, this converts the tumor cell into
a tumor–antigen-presenting cell that is capable of activating naı̈ve T cells
[121,122]. The use of an allogeneic breast cancer vaccine that is genetically
modified to express CD80 is under clinical investigation [123–125].
Dendritic cell vaccines
When exposed to tumor-associated antigens and inflammatory cytokines,
dendritic cells (DCs) take up, process, and present these antigens to naı̈ve
CD8þ and CD4þ lymphocytes, and thus, initiate cellular and humoral
responses against the tumor in question [126]. DCs are believed by many
investigators to be the optimal avenue through which to initiate active anti-
tumor immunity and presumably are involved somewhere in the immune
response pathway for most of the vaccines that were described above. DC
vaccines seek to bypass the need for the recruitment and processing of
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express tumor antigens to the patient [127]. This approach is being in-
vestigated in breast cancer [128,129].
After dendritic cells are obtained from the patient through leukapheresis,
the best method of priming the DC with the appropriate antigens is still
being investigated. Two approaches are to expose immature DCs to tumor
lysates or to fuse DCs with tumor cells. This allows for MHC class I and
class II epitopes and the diversification of immune responses. This approach
is attractive in that immune responses can be generated without the need for
the characterization of tumor-specific antigens. Like autologous cellular
vaccines, it only is applicable to the minority of patients who have breast
cancer in whom enough tumor may be harvested. Additionally, breast
tumors typically have dense connective tissue stroma from which it can be
difficult to release the tumor cells without affecting their viability [130].
Another method is to load exogenous peptides onto the empty MHC class I
molecules of mature DCs. DCs that are pulsed with HER-2/neu or MUC-1
[131], carcinoembryonic antigen (CEA) [132], or mammaglobin-A [133] are
capable of stimulating antigen-specific immune responses.
In situ vaccination
Many of the methods for stimulating an immune response require the
harvesting of tumor, including harvesting TILs for adoptive immunotherapy
or tumor cells for autologous or DC vaccines. Because these methods use
autologous tissue, they can be the most immunogenic; however, the
impediments to obtaining this tissue limits these approaches for immuno-
therapy of breast cancer. One promising approach for breast cancer may be
that of in situ vaccination. Although most vaccines are created ex vivo and
delivered to the patient to stimulate an immune response, in situ vaccination
uses immunostimulatory agents to generate an immune response to the tumor
in vivo. This can be done as a treatment for stage IV disease and circumvents
the need to generate cell lines from resected metastatic deposits or can be
done before surgical resection as a form of neoadjuvant immunotherapy.
In situ vaccination centers primarily on the use of cytokines to generate
the immune response. Because local cytokine production is involved in
inflammation and local immune reactions, the goal of using systemic
cytokines is to achieve clinically-relevant levels at the site of the tumor. To
do this, high systemic doses are required; IV administration has been
associated with significant systemic toxicity and only limited effects on the
tumors. Local delivery may reflect more physiologically-relevant effects than
does systemic cytokine administration. Direct injection of GM-CSF [134],
IL-12 [135], or interferons [136] into the tumor induced lesion regression;
however, this approach is limited by the short half-life of most cytokines and
the need for frequent injections. By delivering low doses of cytokines in
a sustained fashion into the microenvironment of the tumor mass it may be
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without the systemic toxicities. Several studies demonstrated that the
cytokine microenvironment at the tumor site has a significant impact on the
outcome of the immune response, including the use of IL-2 [137,138], IL-4
[139,140], or IL-12 [141]. An improved ability of IL-12 to induce long-term
immunity was observed following peri-tumoral injections [142].
In situ vaccination would overcome the significant toxicities that result
from the high systemic doses of cytokines that are required to achieve
therapeutic dose levels within the tumor. It does not require the
identification of specific tumor antigens, which have been limited in breast
cancer. Most importantly, most of these approaches do not require the
harvesting of tumor cells from the patient, which has been a limiting factor
in the translation of several immunotherapeutic approaches to the treatment
of breast cancer. Several methods have been used to obtain high levels of
cytokines in the tumor microenvironment.
Gene-modified cells
One popular vaccine strategy is to use autologous tumor cells that are
transfected with the gene for a cytokine ex vivo, but it requires the
establishment of a primary culture. This may not be applicable in breast
cancer, where the ability to develop a primary culture is more challenging.
In addition, selection of transfected cells may require prolonged culture,
which may alter expression of nominal tumor antigens. This approach,
however, can be used as an alternative method for in situ vaccination.
Instead of transfecting autologous tumor cells, nontumor cells may be
modified genetically to secrete cytokines and can be injected at the site of
a tumor to obtain paracrine secretion into the tumor microenvironment.
Direct injection of IL-12–transduced fibroblasts effectively eliminated
established tumors in a murine model [143]. This approach also resulted
in the induction of effective systemic immunity. In a phase I trial, IL-12–
secreting fibroblasts led to partial responses in patients who had melanoma,
breast cancer, and head and neck tumors; some persisted for up to 2 years
[144].
The intratumoral delivery of DCs also may stimulate systemic immunity.
To prime DCs with whole tumor cell lysates would be difficult in breast
cancer. Immature DCs can acquire antigen from apoptotic cells and
stimulate antigen-specific CTL [145] and the presence of increased DCs
within solid tumor masses may correlate with an improved prognosis
[146,147]. The intratumoral delivery of DCs can inhibit established breast
tumor growth in a CD8þ-dependent fashion and shows potential for a DC-
based immunotherapy strategy [148].
In vivo transfection
An alternate approach to injecting transfected cells at the tumor site is
the transfection of the gene directly into the tumor cells in vivo. This can be
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for gene therapy for cancer has been investigated for several tumors [149–
151]. Based on the observation that tumor cells that were transduced ex vivo
with retroviruses that expressed cytokines enhanced tumor immunotherapy
[152,153], interest turned toward transducing tumor cells in vivo. This
approach initiated the development of systemic antitumor immunity when
vectors that contained the genes for IL-12 [154–156], GM-CSF [157], and
IL-2 [158] were used. Intratumoral delivery of IL-2 by adenoviral infection
resulted in the regression of local and distant sites in murine breast cancer
models [159–161]. In addition, animals that showed a complete response
developed protective immunity to rechallenge. These results led to a phase
I clinical trial in patients who had metastatic breast cancer and melanoma
[162]. At the site of injection, incomplete local tumor regression was seen in
24% of patients; postinjection biopsies demonstrated tumor necrosis and
lymphocytic infiltration of CD8þ cells.
Biodegradable controlled-release polymers
Although the use of in vivo gene transfer and gene-modified cells have
had some encouraging results, the current gene transfer technologies may
lack the versatility that is required for clinical application [163,164]. The
development of more clinically-feasible and less expensive alternative
technologies for the delivery and sustained release of cytokines to the
tumor microenvironment can enhance significantly the clinical implementa-
tion of cytokine-based breast cancer immunotherapies. Local and sustained
in vivo delivery of therapeutic agents also can be achieved with biodegrad-
able controlled-release polymers [165]. Biodegradable polymer microspheres
have been used for in vivo drug delivery [166], vaccination with antigenic
peptides [167], systemic protein delivery [168], and cancer immunotherapy
[169,170]. Recent advances in encapsulation technologies led to the
successful encapsulation of immunostimulatory cytokines [168]. These
encapsulated cytokines stimulated antitumor responses using GM-CSF
[169] and IL-1a [170] in murine models.
Recently, a novel technology for highly-efficient encapsulation of
biologically-active molecules into poly-lactic acid microspheres (PLAMs)
was described. Phase inversion nano-encapsulation results in the efficient
encapsulation of labile proteins without significant denaturation or losses of
bioactivity. Human cytokine-loaded PLAMs release physiologically-relevant
quantities of bioactive cytokines for extended periods of time in vivo.
Intratumoral injections of IL-2–loaded microspheres provoked an NK cell–
mediated suppression of human tumor xenografts in severe combined
immunodeficiency (SCID) mice [171]. Treatment of tumor-bearing mice with
a single intratumoral injection of PLAM that was loaded with recombinant
IL-12 promoted complete regression of the primary tumor and prevented the
metastatic spread to the lung [172]. This technique was superior to tumor
vaccination, bolus injection of free IL-12, and other routes of administration.
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where adjuvant postoperative vaccinesmay not be feasible (eg, breast cancer).
In murine models, preoperative intratumoral injection of IL-12–loaded
PLAM 1 week before surgical resection resulted in significantly reduced local
recurrence and distant metastases [173]. Cytokine cocktails of IL-12 with
GM-CSF or TNF-a further improved upon these results and resulted in
reduced recurrence of primary tumors, eradicated established metastatic
disease, and improving postoperative survival [174,175] This approach shows
strong potential as neoadjuvant immunotherapy for breast cancer [175].
Obstacles to immunotherapy in breast cancer
Much of the emphasis in this avenue of research has centered on the
creation of an immune response to breast cancer–specific antigens and
success is determined by the presence of serum antibodies that recognize
tumor antigens or cytolytic activity demonstrated in PBMC. This is only
half of the story because a clinically-relevant immune response is two-tiered.
It begins with the generation of antibodies or cytotoxic T cells that can
recognize breast cancer–specific antigens. There is a second tier to that
response–the ability of those antibodies or T cells to recognize cells that
express those antigens and to kill the malignant cells.
Breast cancers are not passive bystanders to the immune response; they
develop mechanisms to evade immune recognition. Breast cancers have been
present in the body for a considerable time before being diagnosed and have
reached this point despite ongoing immune surveillance. Humoral responses
are limited by the fact that monoclonal antibodies have poor penetration
into solid tumors which limits their effectiveness in stage IV disease. Cancers
can escape immune recognition by way of single-antigen vaccines simply
through antigenic modulation. Because a population of tumor cells develops
resistance to a chemotherapeutic agent, the chemotherapy will not cure the
cancer. Likewise, if a subpopulation of cancer cells no longer expresses the
protein or ganglioside it is vaccinated against, it is no longer susceptible to
that immunotherapy. Patients who have progressive disease after immuno-
therapy often exhibit ‘‘antigen loss.’’ In the case of T-cell–based therapies,
tumor cells that lose the ability to bind antigen to MHC and express the
MHC on the cell surface also would escape immune recognition. Many
primary and metastatic breast cancers have lost this ability [176,177].
In breast cancer, the potential success of immunotherapy may be
hampered by the prospect that the immune system might be facilitating
tumor growth. A lymphocytic infiltrate was shown to be a poor prognostic
finding [24]; immunosuppression does not increase the incidence of breast
cancer and it may decrease it [22]. Nonspecific immunostimulants may
worsen outcome [178], whereas immunosuppressive therapies (eg, cortico-
steroids) may give positive results [179]. How could the immune system,
intuitively believed to be ‘‘on our side’’ in fighting cancer, betray us in this
21M.S. Sabel, M.A. Nehs / Surg Oncol Clin N Am 14 (2005) 1–31manner? Tumor-infiltrating lymphocytes may be producing cytokines and
other factors that are favorable to breast cancer cells. Several of these
factors are listed in Table 3.
There are many approaches to breast cancer immunotherapy. It will not
be possible to test every new approach in large randomized trials, especially
considering the multiple adjuvant therapies that already have proven
effective in breast cancer. Another area of research that has lagged behind
the ability to stimulate an immune response is identifying more clinically-
relevant surrogate markers for the generation of an immune response. The
methods for in vitro monitoring of immune responses remain crude
compared with the methods for stimulating those responses. The relevance
of this is clear when one looks at the number of studies in breast cancer in
which the immunotherapy was able to stimulate antigen-specific antibodies
to T cells, but there was no evidence of a clinical response. It is imperative to
design better methods for defining ‘‘success’’ in a phase II trial before we
start accruing the thousands of patients that is necessary to demonstrate an
improved survival in a phase III trial.
The evidence is overwhelming that it is possible to generate an immune
response to breast cancer in some, if not all, patients and that early successes
must be built upon aggressively. It is important that we focus that effort on:
(1) the design of new methods of generating an immune response; (2)
overcoming the immunosuppressive factors that prevent clinical success;
and (3) improving monitoring strategies to allow us to identify effective
therapies. We also must center our efforts toward patients who have breast
cancer patients on strategies that can be integrated into a multi-modality
approach. It is important to realize that methods that are costly and labor-
intensive are going to be difficult to use in the adjuvant setting; this is where
immunotherapy is most likely to have an impact. Additionally, strategies
that are dependent upon autologous tumor are going to be limited severely
in women who have breast cancer. The application of immunotherapy to the
treatment of breast cancer faces several obstacles; however, the prospect of
Table 3
Factors produced by tumor-infiltrating lymphocytes that may favor breast cancer
Factor Benefit to breast cancer Reference
IL-6 Enhanced motility and increased cell-cell separation [180]
IL-8 Increases invasiveness of breast cancer [181,182]
IL-10 Suppresses cellular immune responses [183]
CSF-1 Mediator of breast cancer invasion and metastases [184]
HB-EGF Stimulates breast cancer proliferation [185]
bFGF Stimulates proliferation, angiogenic [185]
VEGF Stimulates breast cancer proliferation [186]
TNF-a Stimulates proliferation, motility [187,188]
Prolactin Stimulates proliferation [189]
Abbreviations: bFGF, basic fibroblast growth factor; HB-EGF, heparin-binding epidermal
growth factor; VEGF, vascular endothelial growth factor.
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sufficiently realistic to justify the extensive research effort that is necessary to
make this a reality.
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